fda warning glp-1 compounding september 2025 Beyond the Headlines: Letters to Compounders The FDA should require negative

Research suggests a slow build across the activation and consolidation phases rather than an overnight effect

Dose titration during the first week prevents common adverse events

For compounding pharmacies or physicians that have been compounding semaglutide products during the shortage, the FDA has set clear deadlines for ceasing general semaglutide compounding practices: State-licensed pharmacies or physicians compounding semaglutide under Section 503A of the FD&C Act must stop compounding, distributing, or dispensing semaglutide injections that are essentially copies of an FDA-approved product by April 22, 2025

Terpene Targeting: Enter Humulene Not all cannabis is created equal

Once usage stops, effects fade within weeks

These processes are essential for gut repair